- Home
- COEP vs LSTA Comparison
COEP vs LSTA Comparison
Compare COEP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- LSTA
- Stock Information
- Founded
- COEP 2017
- LSTA 1980
- Country
- COEP United States
- LSTA United States
- Employees
- COEP N/A
- LSTA N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- LSTA Misc Health and Biotechnology Services
- Sector
- COEP Health Care
- LSTA Health Care
- Exchange
- COEP Nasdaq
- LSTA Nasdaq
- Market Cap
- COEP 62.4M
- LSTA 22.3M
- IPO Year
- COEP N/A
- LSTA N/A
- Fundamental
- Price
- COEP $12.61
- LSTA $2.27
- Analyst Decision
- COEP
- LSTA Strong Buy
- Analyst Count
- COEP 0
- LSTA 2
- Target Price
- COEP N/A
- LSTA $23.50
- AVG Volume (30 Days)
- COEP 39.8K
- LSTA 21.9K
- Earning Date
- COEP 11-12-2025
- LSTA 11-11-2025
- Dividend Yield
- COEP N/A
- LSTA N/A
- EPS Growth
- COEP N/A
- LSTA N/A
- EPS
- COEP N/A
- LSTA N/A
- Revenue
- COEP $263,555.00
- LSTA $1,070,000.00
- Revenue This Year
- COEP N/A
- LSTA N/A
- Revenue Next Year
- COEP N/A
- LSTA N/A
- P/E Ratio
- COEP N/A
- LSTA N/A
- Revenue Growth
- COEP N/A
- LSTA N/A
- 52 Week Low
- COEP $2.31
- LSTA $1.87
- 52 Week High
- COEP $14.70
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- COEP 52.79
- LSTA 45.72
- Support Level
- COEP $12.09
- LSTA $2.11
- Resistance Level
- COEP $13.25
- LSTA $2.28
- Average True Range (ATR)
- COEP 0.73
- LSTA 0.16
- MACD
- COEP -0.11
- LSTA -0.00
- Stochastic Oscillator
- COEP 49.65
- LSTA 36.83
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.